Behavioral and cognitive effects of docosahexaenoic acid in drug-naïve children with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled clinical trial

Alessandro Crippa, Alessandra Tesei, Federica Sangiorgio, Antonio Salandi, Sara Trabattoni, Silvia Grazioli, Carlo Agostoni, Massimo Molteni, Maria Nobile

Research output: Contribution to journalArticle

Abstract

This study aimed to investigate the efficacy of docosahexaenoic acid (DHA) dietary supplementation on behavior and cognition in school-aged, drug-naïve children with attention-deficit/hyperactivity disorder (ADHD). A total of 50 participants with ADHD aged 7 to 14 were enrolled in a 6-month randomized, placebo-controlled clinical trial and received either DHA or placebo. The primary outcome measure was the change in the ADHD rating scale IV Parent Version–Investigator (ADHD-RS-IV) after 4 and 6 months. Secondary outcome measures included Conners Parent Rating Scale-revised, other behavioral rating scales including quality of life and global functioning, and computerized cognitive tasks. Baseline assessment also addressed the blood fatty acids profile. No superiority of DHA supplement to placebo was observed on ADHD-RS-IV, the a priori primary outcome. DHA supplementation showed a significant, nonetheless quite small, effect on children’s psychosocial functioning, emotional problems, and focused attention. Neither major nor minor adverse events were reported throughout the trial. This study shows that 6-month DHA supplementation has no beneficial effect on the symptoms of ADHD in school-aged, drug-naïve children with an established diagnosis of ADHD. Nevertheless, the 6 months treatment with supplemental DHA appears to have small positive effects on other behavioral and cognitive difficulties, which, in light of the absence of side-effects, could be reasonably followed up in future intervention studies. (https://clinicaltrials.gov/ct2/show/NCT01796262: The Effects of DHA on Attention Deficit and Hyperactivity Disorder (DADA)).

Original languageEnglish
JournalEuropean Child and Adolescent Psychiatry
DOIs
Publication statusE-pub ahead of print - Jan 1 2018

Fingerprint

Docosahexaenoic Acids
Attention Deficit Disorder with Hyperactivity
Randomized Controlled Trials
Placebos
Pharmaceutical Preparations
Outcome Assessment (Health Care)
Dietary Supplements
Cognition
Fatty Acids
Quality of Life

Keywords

  • Attention-deficit/hyperactivity disorder (ADHD)
  • Behavior
  • Cognition
  • Docosahexaenoic acid (DHA)
  • Fatty acids

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Developmental and Educational Psychology
  • Psychiatry and Mental health

Cite this

@article{181642e56c624a988a5930107e4354e3,
title = "Behavioral and cognitive effects of docosahexaenoic acid in drug-na{\"i}ve children with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled clinical trial",
abstract = "This study aimed to investigate the efficacy of docosahexaenoic acid (DHA) dietary supplementation on behavior and cognition in school-aged, drug-na{\"i}ve children with attention-deficit/hyperactivity disorder (ADHD). A total of 50 participants with ADHD aged 7 to 14 were enrolled in a 6-month randomized, placebo-controlled clinical trial and received either DHA or placebo. The primary outcome measure was the change in the ADHD rating scale IV Parent Version–Investigator (ADHD-RS-IV) after 4 and 6 months. Secondary outcome measures included Conners Parent Rating Scale-revised, other behavioral rating scales including quality of life and global functioning, and computerized cognitive tasks. Baseline assessment also addressed the blood fatty acids profile. No superiority of DHA supplement to placebo was observed on ADHD-RS-IV, the a priori primary outcome. DHA supplementation showed a significant, nonetheless quite small, effect on children’s psychosocial functioning, emotional problems, and focused attention. Neither major nor minor adverse events were reported throughout the trial. This study shows that 6-month DHA supplementation has no beneficial effect on the symptoms of ADHD in school-aged, drug-na{\"i}ve children with an established diagnosis of ADHD. Nevertheless, the 6 months treatment with supplemental DHA appears to have small positive effects on other behavioral and cognitive difficulties, which, in light of the absence of side-effects, could be reasonably followed up in future intervention studies. (https://clinicaltrials.gov/ct2/show/NCT01796262: The Effects of DHA on Attention Deficit and Hyperactivity Disorder (DADA)).",
keywords = "Attention-deficit/hyperactivity disorder (ADHD), Behavior, Cognition, Docosahexaenoic acid (DHA), Fatty acids",
author = "Alessandro Crippa and Alessandra Tesei and Federica Sangiorgio and Antonio Salandi and Sara Trabattoni and Silvia Grazioli and Carlo Agostoni and Massimo Molteni and Maria Nobile",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s00787-018-1223-z",
language = "English",
journal = "European Child and Adolescent Psychiatry",
issn = "1018-8827",
publisher = "Dr. Dietrich Steinkopff Verlag GmbH and Co. KG",

}

TY - JOUR

T1 - Behavioral and cognitive effects of docosahexaenoic acid in drug-naïve children with attention-deficit/hyperactivity disorder

T2 - a randomized, placebo-controlled clinical trial

AU - Crippa, Alessandro

AU - Tesei, Alessandra

AU - Sangiorgio, Federica

AU - Salandi, Antonio

AU - Trabattoni, Sara

AU - Grazioli, Silvia

AU - Agostoni, Carlo

AU - Molteni, Massimo

AU - Nobile, Maria

PY - 2018/1/1

Y1 - 2018/1/1

N2 - This study aimed to investigate the efficacy of docosahexaenoic acid (DHA) dietary supplementation on behavior and cognition in school-aged, drug-naïve children with attention-deficit/hyperactivity disorder (ADHD). A total of 50 participants with ADHD aged 7 to 14 were enrolled in a 6-month randomized, placebo-controlled clinical trial and received either DHA or placebo. The primary outcome measure was the change in the ADHD rating scale IV Parent Version–Investigator (ADHD-RS-IV) after 4 and 6 months. Secondary outcome measures included Conners Parent Rating Scale-revised, other behavioral rating scales including quality of life and global functioning, and computerized cognitive tasks. Baseline assessment also addressed the blood fatty acids profile. No superiority of DHA supplement to placebo was observed on ADHD-RS-IV, the a priori primary outcome. DHA supplementation showed a significant, nonetheless quite small, effect on children’s psychosocial functioning, emotional problems, and focused attention. Neither major nor minor adverse events were reported throughout the trial. This study shows that 6-month DHA supplementation has no beneficial effect on the symptoms of ADHD in school-aged, drug-naïve children with an established diagnosis of ADHD. Nevertheless, the 6 months treatment with supplemental DHA appears to have small positive effects on other behavioral and cognitive difficulties, which, in light of the absence of side-effects, could be reasonably followed up in future intervention studies. (https://clinicaltrials.gov/ct2/show/NCT01796262: The Effects of DHA on Attention Deficit and Hyperactivity Disorder (DADA)).

AB - This study aimed to investigate the efficacy of docosahexaenoic acid (DHA) dietary supplementation on behavior and cognition in school-aged, drug-naïve children with attention-deficit/hyperactivity disorder (ADHD). A total of 50 participants with ADHD aged 7 to 14 were enrolled in a 6-month randomized, placebo-controlled clinical trial and received either DHA or placebo. The primary outcome measure was the change in the ADHD rating scale IV Parent Version–Investigator (ADHD-RS-IV) after 4 and 6 months. Secondary outcome measures included Conners Parent Rating Scale-revised, other behavioral rating scales including quality of life and global functioning, and computerized cognitive tasks. Baseline assessment also addressed the blood fatty acids profile. No superiority of DHA supplement to placebo was observed on ADHD-RS-IV, the a priori primary outcome. DHA supplementation showed a significant, nonetheless quite small, effect on children’s psychosocial functioning, emotional problems, and focused attention. Neither major nor minor adverse events were reported throughout the trial. This study shows that 6-month DHA supplementation has no beneficial effect on the symptoms of ADHD in school-aged, drug-naïve children with an established diagnosis of ADHD. Nevertheless, the 6 months treatment with supplemental DHA appears to have small positive effects on other behavioral and cognitive difficulties, which, in light of the absence of side-effects, could be reasonably followed up in future intervention studies. (https://clinicaltrials.gov/ct2/show/NCT01796262: The Effects of DHA on Attention Deficit and Hyperactivity Disorder (DADA)).

KW - Attention-deficit/hyperactivity disorder (ADHD)

KW - Behavior

KW - Cognition

KW - Docosahexaenoic acid (DHA)

KW - Fatty acids

UR - http://www.scopus.com/inward/record.url?scp=85053846980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053846980&partnerID=8YFLogxK

U2 - 10.1007/s00787-018-1223-z

DO - 10.1007/s00787-018-1223-z

M3 - Article

AN - SCOPUS:85053846980

JO - European Child and Adolescent Psychiatry

JF - European Child and Adolescent Psychiatry

SN - 1018-8827

ER -